What should you know about IDH mutant glioma?

The change is usually identified by analysing tumour tissue for IDH1 or IDH2. It is a molecular feature of the tumour, not something diagnosed from symptoms alone. Specialists combine it with the tumour type, grade, location, imaging, and other markers to create the diagnosis. The result can help distinguish glioma groups, but it cannot describe the entire outlook for one person.

A glioma may affect movement, sensation, speech, vision, memory, or seizure control according to its position in the brain. Symptoms can develop gradually or appear suddenly. Some people are diagnosed after a scan for an unrelated concern.

Ask whether the sample was large enough for the molecular tests and whether the report includes other important markers. Depending on grade and location, options may include monitoring with scans, [Brain Tumour Surgery], [Radiotherapy], medicines, rehabilitation, or supportive care. Surgery is planned around removing tumour while protecting speech, movement, vision, and other brain functions.

Keep a record of seizures, headaches, medication effects, and changes in work or daily tasks. Ask who will review scans and what the plan is if symptoms change between appointments.

Get urgent help for a first seizure, a seizure that continues beyond the duration in your emergency plan, sudden weakness, new speech or vision difficulty, loss of consciousness, or severe confusion. Contact the treating team quickly after surgery for fever, wound drainage, increasing swelling, unusual sleepiness, or a new neurological symptom.

Is the result an IDH1 or IDH2 mutation? What tumour type and grade does it support? Which additional markers were checked? Should we monitor, operate, or start another treatment? What brain functions are near the tumour? How will seizures and treatment effects be managed?